FierceDrugDelivery spoke with the prolific drug delivery expert about the field's future, regarding nanotechnology in particular, as well as some of the projects Langer's lab and various business ventures are undertaking currently to make next-gen nanomedicine a reality.
MIT professor and biotech entrepreneur Robert Langer and colleagues have created a synthetic version of the natural high-density lipoprotein--or "good cholesterol"--for use in drug delivery to treat cardiovascular diseases such as atherosclerosis.
Yet another biotech has joined the raging IPO craze. Nanomedicine company Bind Therapeutics has raised $70.5 million in a public offering of its stock priced at $15 per share, The Associated Press reports.
Researchers at MIT are working on new ways to carry RNAi drugs via liquid nanoparticles that would maximize their delivery and their ability to silence malfunctioning genes that can lead to cancer.
In a piece for Nature Biotechnology, serial biotech entrepreneur and MIT professor Robert Langer shared some of his experiences in launching more than two dozen biotechs over the past 26 years.
Taris Biomedical has gone back to the venture well as the biotech startup launches a midstage study of its lead candidate against bladder pain. The Lexington, MA-based company found support for its latest financing from previous backers at Flybridge Capital Partners, Flagship Ventures, Polaris Venture Partners and Third Rock Ventures.
Our readers hunger for context and analysis of major developments in the industry. We work hard to deliver such insights in all of our daily reports. Yet we aim to go deeper into stories with additional feature articles and special reports.
T2 Biosystems pulled in a whopping $40 million Series E funding round to support clinical testing and a commercial launch of the company's Candida infection rapid diagnostic assay.
Living Proof has another $30 million in venture cash to get commercialization work in gear, while bankrolling some fresh efforts on the scientific side of the hair care venture.
When it comes to drug delivery, it's hard these days to overlook the buzzing field of nanoengineering. Highly targeted nanoparticles are on the cutting edge of the growing field, and according to BIND Biosciences' Jeff Hrkach, there are big things in store for the tiny drug carriers.